BG
NTLA icon

BlackRock Group’s Intellia Therapeutics NTLA Stock Holding History

BlackRock Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$29K Hold
2,191
– – ﹤0.01% 2949
2016
Q3 		$37K Hold
2,191
– – ﹤0.01% 2942
2016
Q2 		$47K Buy
+2,191
New +$58.3K ﹤0.01% 2926

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock Group's NTLA Position: Q4 2016 in Review

BlackRock Group held its Intellia Therapeutics (NTLA) position steady in Q4 2016 at 2,191 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

BlackRock Group first reported a position in NTLA in Q2 2016 and has held it in 3 quarters since. The position peaked at $47K in Q2 2016. 70 funds tracked by Wall St. Rank hold NTLA as of Q4 2016.

  • BlackRock Group held 2,191 shares of Intellia Therapeutics worth $29K as of Q4 2016.
  • BlackRock Group left its Intellia Therapeutics share count unchanged in Q4 2016.
  • Intellia Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2949 holding.
  • BlackRock Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • BlackRock Group's Intellia Therapeutics position peaked at $47K in Q2 2016.
  • 70 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.